247 Users Online
U.S Polycystic Ovarian Syndrome Treatment Market Segmented By Oral Contraceptives, Insulin Sensitizing Agents, Anti-Depressants, Ornithine, Decarboxylase Inhibitors, Aromatase Inhibitors and SERMs, Diuretics Drug Class
1. Executive Summary
2. Market Introduction
2.1. Market Definition
2.2. Market Taxonomy
3. Market Analysis Scenario
3.1. Market Size (US$ Mn) and Forecast
3.1.1. Market Size and Y-o-Y Growth
3.1.2. Absolute $ Opportunity
3.2. Market Overview
3.2.1.Value Chain
4. Market Dynamics
4.1. Macro-economic Factors
4.2. Drivers
4.2.1. Supply Side
4.2.2. Demand Side
4.3. Restraints
4.4. Opportunity
4.5. Forecast Factors – Relevance and Impact
4.6. Disease Epidemiology (2015)
4.7. Prescription and Average Duration of Treatment
4.8. Case Study
5. U.S. Polycystic Ovary Syndrome Treatment Market Analysis and Forecast, By Drug Class
5.1. Introduction
5.1.1.Basis Point Share (BPS) Analysis By Drug Class
5.1.2.Y-o-Y Growth Projections By Drug Class
5.2. Market Size (US$ Mn) and Forecast By Drug Class
5.2.1. Contraceptives
5.2.2. Insulin Sensitizing Agents
5.2.3. Anti-Depressants
5.2.4. Ornithine Decarboxylase Inhibitors
5.2.5. Aromatase Inhibitors & SERMs
5.2.6. Diuretics Market Attractiveness Analysis By Drug Class
5.3. U.S. Polycystic Ovary Syndrome Treatment Market Attractiveness Analysis By Drug Class
6. U.S. Polycystic Ovary Syndrome Treatment Market Analysis and Forecast, By Distribution Channel
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis By Distribution Channel
6.1.2. Y-o-Y Growth Projections By Distribution Channel
6.2. Market Size (US$ Mn) Forecast By Distribution Channel
6.2.1. Hospitals Pharmacies
6.2.2. Drugs Store/OTC
6.2.3. E-Commerce
6.2.4. Fertility Clinics
6.3. U.S. Polycystic Ovary Syndrome Treatment Market Attractiveness Analysis, By Distribution Channel
7. Competition Landscape
7.1. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
7.2. Key Players
7.2.1. Revenue
7.2.2. Company Highlights
7.2.3. Key Players
7.2.3.1. Sanofi
7.2.3.2. Novartis AG
7.2.3.3. Teva Pharmaceutical Industries Limited
7.2.3.4. Merck KGaA
7.2.3.5. AstraZeneca
8. Assumptions and Acronyms Used
9. Research Methodology
FREE Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
List of Tables
Table 01: U.S. Polycystic Ovary Syndrome Drugs Market Value Analysis, by Drug Class, 2015–2024 (US$ Mn)
Table 02: U.S. Polycystic Ovary Syndrome Drugs Value Analysis, by Distribution Channel, 2015–2024 (US$ Mn)
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
List of Figures
Figure 1. U.S. Polycystic Ovary Syndrome Drugs Market Value Share By, Drug Class, 2016
Figure 2. U.S. Polycystic Ovary Syndrome Drugs Market Value Share By, Distribution Channel, 2016
Figure 3: U.S. Polycystic Ovary Syndrome Drugs Market Value, US$ Mn, 2015–2024
Figure 4: U.S. Polycystic Ovary Syndrome Drugs Market Share Analysis, by Drug Class Type (%), 2016–2024
Figure 5: U.S. Polycystic Ovary Syndrome Drugs Market Y-o-Y Growth (%), by Drug Class, 2016–2024
Figure 6: U.S. Polycystic Ovary Syndrome Drugs Market Attractiveness Index, by Drug Class, 2016–2024
Figure 7: U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Contraceptives, 2016 – 2024
Figure 8: U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Contraceptives Segment, 2016 – 2024 (US$ Mn
Figure 9: U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Insulin Sensitizing Agents, 2016 – 2024
Figure 10: U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Insulin Sensitizing Agents Segment, 2016 – 2024 (US$ Mn)
Figure 11: U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Anti-Depressants, 2016 – 2024
Figure 12: U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Anti-Depressants Segment, 2016 – 2024 (US$ Mn)
Figure 13: U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Ornithine Decarboxylase Inhibitors, 2016 – 2024
Figure 14: U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Ornithine Decarboxylase Inhibitors Segment, 2016 – 2024 (US$ Mn)
Figure 15: U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Aromatase Inhibitors & SERMs, 2016 – 2024
Figure 16: U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Aromatase Inhibitors & SERMs Segment, 2016 – 2024 (US$ Mn)
Figure 17: U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Diuretics, 2016 – 2024
Figure 18: U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Diuretics Segment, 2016 – 2024 (US$ Mn)
Figure 19: U.S. Polycystic Ovary Syndrome Drugs Market Share Analysis, by Distribution Channel (%), 2016 & 2024
Figure 20: U.S. Polycystic Ovary Syndrome Drugs Market Y-o-Y Growth (%), by Distribution Channel, 2016–2024
Figure 21: U.S. Polycystic Ovary Syndrome Drugs Market Attractiveness Index, by Distribution Channel, 2016–2024
Figure 22: U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2016 – 2024
Figure 23: U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Hospital Pharmacies, 2016 – 2024 (US$ Mn)
Figure 24: U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Drug Stores/OTC, 2016 – 2024
Figure 25: U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Drug Stores/OTC, 2016 – 2024 (US$ Mn)
Figure 26: U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by E-commerce, 2016 – 2024
Figure 27: U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by E-commerce, 2016 – 2024 (US$ Mn)
Figure 28: U.S. Polycystic Ovary Syndrome Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Fertility Clinics, 2016 – 2024
Figure 29: U.S. Polycystic Ovary Syndrome Drugs Market Absolute $ Opportunity, by Fertility Clinics, 2016 – 2024 (US$ Mn)
